dulaglutide Trulicity
Selected indexed studies
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. (Lancet, 2019) [PMID:31189511]
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. (Am Heart J, 2024) [PMID:37758044]
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. (N Engl J Med, 2025) [PMID:41406444]
_Worker-drafted node — pending editorial review._
Connections
dulaglutide Trulicity is a side effect of
Sources
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. (2019) pubmed
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. (2018) pubmed
- Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. (2024) pubmed
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. (2025) pubmed
- Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. (2022) pubmed
- Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial. (2025) pubmed
- Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. (2022) pubmed
- Effects of dulaglutide on alcohol consumption during smoking cessation. (2023) pubmed
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. (2021) pubmed
- Dulaglutide (Trulicity)-Induced Acute Pancreatitis: A Case Report. (2023) pubmed